| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| IL6-M5245 | Mouse | Mouse IL-6 Protein, His Tag |  |
|
|
| IL6-H8218 | Human | Biotinylated Human IL-6 Protein, epitope tag free, ultra sensitivity (primary amine labeling) |  |
|
|
| IL6-H4218 | Human | ActiveMax® Human IL-6 Protein, Tag Free |  |
|
|
Biotinylated Human IL-6, epitope tag free, primary amine labeling (Cat. No. IL6-H8218) stimulates proliferation of TF-1 human erythroleukemic cell line. The EC50 for this effect is 0.2532-0.4489 ng/mL (Routinely tested).
Loaded Biotinylated Human IL-6, epitope tag free, primary amine labeling (Cat. No. IL6-H8218) on SA Biosensor, can bind Human IL-6 R alpha, His Tag (Cat. No. ILR-H4223) with an affinity constant of 45.9 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Thalidomide | K-17; NSC-66847; NSC-527179 | Approved | Celgene Corp | Thaled, Synovir, Talizer, Thalomid, Thalidomide Celgene, Thalidomide Pharmion | Japan | Leprosy, Lepromatous | s:23:"Fujimoto Pharmaceutical"; | 1982-01-01 | HIV Infections; Spondylitis, Ankylosing; Myelodysplastic Syndromes; Multiple Myeloma; Erythema Nodosum; HIV Wasting Syndrome; Leprosy, Lepromatous; Carcinoma, Hepatocellular | Details |
| Siltuximab | cCLB-8; CNTO-328 | Approved | Eusa Pharma, Janssen Global Services Llc | Sylvant | EU | Castleman Disease | s:28:"Eusa Pharma (Netherlands) Bv"; | 2014-04-23 | Lung Diseases; Lymphoma, Non-Hodgkin; Lung Neoplasms; Castleman Disease; Colorectal Neoplasms; Neoplasms, Plasma Cell; Prostatic Neoplasms; Multicentric Castleman's Disease (MCD); Monoclonal Gammopathy of Undetermined Significance; Respiratory Distress Syndrome, Adult; Respiratory Tract Infections; Multiple Myeloma; Myelodysplastic Syndromes; Pancreatic Neoplasms; Smoldering Multiple Myeloma; Carcinoma, Renal Cell; Pneumonia; Ovarian Neoplasms; Head and Neck Neoplasms | Details |
| Pomalidomide | CDC-394; CC-4047; IMiD-1; IMID-4047 | Approved | Celgene Corp | Pomalyst, Imnovid, Actimid, Pomalyst/Imnovid, 安跃 | Mainland China | Multiple Myeloma | s:47:"Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd"; | 2013-02-08 | Central Nervous System Neoplasms; Anemia, Sickle Cell; Sarcoma, Kaposi; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Metastasis; Lymphoma, Non-Hodgkin; Primary Myelofibrosis; Lymphoma, Follicular; Prostatic Neoplasms; Sarcoma; Medulloblastoma; Lung Diseases, Interstitial; Multiple Myeloma; Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Scleroderma, Systemic; Lymphoma, B-Cell; Bone Marrow Neoplasms; Solid tumours | Details |
| Lenalidomide | IMID-5013; CDC-5013; CDC-501; ENMD-0997; CC-5013; IMiD-3 | Approved | Celgene Corp | 瑞复美, Revlimid, Revimid (former Brand Name) | EU | Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular | s:17:"Celgene Europe Bv"; | 2005-12-27 | Lymphoma, Mantle-Cell; Carcinoma, Non-Small-Cell Lung; Crohn Disease; Complex Regional Pain Syndromes; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Metastasis; Melanoma; Waldenstrom Macroglobulinemia; Thrombocytopenia; Leukemia, Myeloid, Acute; Lymphoma, T-Cell; Lymphoma, Non-Hodgkin; Reflex Sympathetic Dystrophy; Radiculopathy; Lymphoma, Follicular; Prostatic Neoplasms; Lymphoma, B-Cell, Marginal Zone; Multiple Myeloma; Smoldering Multiple Myeloma; Blood Protein Disorders; Myelodysplastic Syndromes; Leukemia-Lymphoma, Adult T-Cell; Lymphoma, Large B-Cell, Diffuse; Paraproteinemias; Anemia; Lymphoma, B-Cell; HIV Infections; Solid tumours; Hematologic Diseases; Lymphoma, T-Cell, Peripheral; Leukemia, Myeloid | Details |
| Luminol sodium | MP-1032 | Approved | Selvim, Metrio | Psoriasis; Immune System Diseases | s:4:"null"; | 1997-01-01 | Immune System Diseases; Psoriasis | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| PXL-01 | PXL-01 | Phase 3 Clinical | Promore Pharma | Tissue Adhesions; Post-surgical adhesions | Details |
| EBI-031 | EBI-031 | Phase 1 Clinical | Sesen Bio | Diabetic macular oedema; Uveitis | Details |
| FB-704A | FB-704; FB-704A | Phase 1 Clinical | Fountain Biopharma | Arthritis, Rheumatoid | Details |
| Tocilizumab biosimilar (Mycenax Biotech) | Phase 1 Clinical | Mycenax Biotech | Arthritis, Rheumatoid | Details | |
| Anti-interleukin-6 receptor monoclonal antibody (Biocad) | Phase 2 Clinical | Biocad | Autoimmune Diseases | Details | |
| Gerilimzumab | GB-224; RYI-008; ARGX-109 | Phase 2 Clinical | Argen-X | Arthritis, Rheumatoid | Details |
| Cis-urocanic acid | Cis-UCA; UCA-001; UCA-002 | Phase 2 Clinical | Herantis Pharma | Dry Eye Syndromes; Urinary Bladder Neoplasms; Xerophthalmia; Dermatitis, Atopic | Details |
| DMT-210 | DMT-200; DMT-210; DMT-220; SIG-990 | Phase 2 Clinical | Signum Dermalogix | Rosacea; Dermatitis, Atopic | Details |
| PF-04236921 | PF-4236921; PF-04236921 | Phase 2 Clinical | Pfizer Pharmaceuticals Ltd (China) | Arthritis, Rheumatoid; Lupus Erythematosus, Systemic; Crohn Disease | Details |
| Olokizumab | CDP-6038; Anti-IL6-UCB | Phase 3 Clinical | Ucb | Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Arthritis; Crohn Disease | Details |
| HL-2351 | GX-P4; HL-2351; rhIL-1Ra-hyFc | Phase 2 Clinical | Genexine Inc | Arthritis, Rheumatoid; Cryopyrin-Associated Periodic Syndromes | Details |
| MEDI-5117 | WBP-216; MEDI-5117 | Phase 1 Clinical | Wuxi Apptec Co Ltd, Medimmune | Arthritis, Rheumatoid | Details |
| Ziltivekimab | COR-001 | Phase 2 Clinical | Astrazeneca Pharmaceutical Co Ltd | Anemia; Renal Insufficiency, Chronic; Inflammation | Details |
| Clazakizumab | ALD-518; ALD518-003; BMS-645429; BMS-945429 | Phase 3 Clinical | Alder Biopharmaceuticals | Anemia; Graft vs Host Disease; Fatigue; Arthritis, Rheumatoid; Rejection of organ transplantation; Arthritis, Psoriatic; Cachexia; Inflammation; Crohn Disease; Carcinoma, Non-Small-Cell Lung; Stomatitis | Details |
| Wogonin | Phase 1 Clinical | Shandong Buchang Pharmaceuticals Co Ltd, Hefei Cosource Medicine Technology, Daewoong Pharmaceutical Co Ltd, China Pharmaceutical University | Respiratory Tract Infections; Neoplasms | Details | |
| CD24-Fc | HAS-CD24; CD24-Fc-IgG; MK-7110; MK7110; CD24-Fc | Phase 3 Clinical | Oncoimmune | HIV Infections; Leukemia; Coronavirus Disease 2019 (COVID-19); Graft vs Host Disease; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Dyslipidemias; Leukemia, Myeloid, Acute; Melanoma | Details |
This web search service is supported by Google Inc.
A-Z
